Cipla Limited (NSE:CIPLA)

India flag India · Delayed Price · Currency is INR
1,228.80
-12.00 (-0.97%)
Apr 20, 2026, 3:30 PM IST
Market Cap1.00T -17.9%
Revenue (ttm)279.67B +4.7%
Net Income45.46B -8.9%
EPS56.25 -8.9%
Shares Out807.78M
PE Ratio22.06
Forward PE23.88
Dividend13.00 (1.05%)
Ex-Dividend DateJun 27, 2025
Volume1,158,467
Average Volume1,848,726
Open1,245.00
Previous Close1,240.80
Day's Range1,226.00 - 1,246.00
52-Week Range1,165.70 - 1,673.00
Beta0.06
RSI44.79
Earnings DateMay 13, 2026

About Cipla

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obe... [Read more]

Sector Healthcare
Founded 1935
Employees 30,313
Stock Exchange National Stock Exchange of India
Ticker Symbol CIPLA
Full Company Profile

Financial Performance

In fiscal year 2025, Cipla's revenue was 272.67 billion, an increase of 6.78% compared to the previous year's 255.37 billion. Earnings were 52.73 billion, an increase of 27.93%.

Financial Statements

News

Cipla receives two inspectional observations from USFDA at Goa facility

Cipla has announced that the United States Food and Drug Administration (USFDA) conducted an inspection at its manufacturing facility in Verna, Goa, India. The inspection, which took place from 6th…

3 days ago - Business Upturn

Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77%

Pharmaceutical sector stocks traded mostly lower in early trade on Monday, April 13, 2026, with most counters under pressure. The S&P BSE Healthcare Index declined 0.88% to 42,246.47, while the…

7 days ago - Business Upturn

Cipla Gets FDA Approval For Generic Nintedanib Capsules

(RTTNews) - Cipla USA Inc. the wholly owned subsidiary of Cipla Limited (500087, CIPLA) announced that it has received final approval from U.S. FDA for Abbreviated New Drug Application or ANDA for Nin...

17 days ago - Nasdaq

Cipla appoints new senior management personnel amid leadership changes

Cipla has announced significant changes in its senior management team as part of a leadership transition. Effective 1st April 2026, Mr Achin Gupta will take charge as the Managing Director…

20 days ago - Business Upturn

Cipla, Bajaj Finserv & more: Top stocks to watch today

Analysts have adjusted targets for several companies, with UBS neutral on Cipla citing supply headwinds despite a healthy pipeline. Motilal Oswal initiated coverage on Bajaj Finserv with a neutral rat...

24 days ago - The Times of India

Cipla's Global Chief Scientific Officer Pradeep Bhadauria resigns

Cipla has announced the resignation of Mr Pradeep Bhadauria, the Global Chief Scientific Officer and a member of the Management Council. Bhadauria, who is also an employee of Cipla USA…

24 days ago - Business Upturn

Nifty 50 top losers today, March 24: Coal India, Power Grid, Adani Enterprises, Sun Pharma and Cipla

Indian equity benchmarks ended on a strong note on March 24, with the Nifty closing above the 22,900 mark. The Sensex gained 1,372.06 points (1.89%) to settle at 74,068.45, while…

27 days ago - Business Upturn

Nifty 50 top losers today, March 18: Hindustan Unilever, Coal India, Cipla, NTPC and more

The Indian equity markets ended lower on March 18, 2026, with benchmark indices witnessing selling pressure across key sectors. The Nifty 50 closed at 23,777.80, down 196.65 points or 0.83%,…

4 weeks ago - Business Upturn

Nifty 50 top losers today, March 17: Wipro, Cipla, Infosys, Tata Consumer Products, ITC and more

Indian benchmark indices ended lower on March 17, with the Nifty 50 closing at 23,581.15, down 172.35 points or 0.74%. Weakness across IT, FMCG and financial stocks weighed on the…

4 weeks ago - Business Upturn

FENC Settles Litigation with Cipla Over PEDMARK Generic Entry

FENC Settles Litigation with Cipla Over PEDMARK Generic Entry

4 weeks ago - GuruFocus

Should you buy, hold, or sell Cipla shares? Here’s what Morgan Stanley recommends

Wednesday, March 11 Shares of Cipla were trading around Rs 1,327.80, down 0.43% in early trade on Wednesday after concerns emerged over supply disruptions in one of the company’s key…

5 weeks ago - Business Upturn

Top Stocks To Buy/Sell Today: HAL, Cipla, Godrej Properties, Aster DM, Ultratech Cement, Adani Ports besides others in focus

Several stocks are expected to remain in focus today following key order wins, regulatory approvals, capacity expansions, mergers and corporate developments announced by companies. Hindustan Aeronauti...

6 weeks ago - Business Upturn

Cipla forms 60:40 JV with Kemwell Biopharma to develop and commercialise biologic products

Cipla Limited has entered into a 60:40 joint venture agreement with Kemwell Biopharma Private Limited on March 2, 2026, for...

6 weeks ago - Business Upturn

Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09%

The Indian pharmaceutical sector showed mixed performance on February 27, 2026, during early morning trading hours. Data from around 9:24...

7 weeks ago - Business Upturn

Cipla shares fall over 2% after USFDA classifies Greece facility inspection as OAI

Shares of Cipla declined more than 2% in early trade after the company disclosed that the United States Food and...

2 months ago - Business Upturn

Top stocks to watch today – February 23: Axis Bank, UPL, Vedanta, Adani Ports, SBI Life, NHPC, IDFC First, Cipla and more

Indian markets are expected to react to a mix of corporate developments, regulatory actions, fund-raising plans, order wins and policy...

2 months ago - Business Upturn

Nifty 50 top losers today, Feb 12: Cipla, Adani Enterprises, Maruti Suzuki India, INDIGO, Adani Ports and more

Indian equity indices ended lower on February 12, with the Nifty closing below the 25,850 mark amid broad-based selling pressure....

2 months ago - Business Upturn

Cipla Launches Win Over Weight Campaign, Igniting a National Conversation on Obesity Care in India

Business Wire India Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of...

2 months ago - Business Upturn

Nifty 50 top losers today, Feb 2: Shriram Finance, Axis Bank, Max Healthcare, Infosys, Cipla and more

Indian equity benchmarks ended the February 2 session on a strong note despite volatility, with the Nifty 50 closing above...

2 months ago - Business Upturn

Top losers among Nifty 50 stocks in midday trade today, Feb 2: Shriram Finance, Cipla, Trent, Infosys, Axis Bank and more

Indian equity benchmarks were trading in positive territory during midday trade on February 2, even as several frontline stocks witnessed...

2 months ago - Business Upturn

Pharma sector stocks today, Feb 2: Cipla down 2%, Lupin falls 1.72%, Torrent Pharma drops 1.92%

The Indian pharma sector showed mixed performance on February 2, 2026, as of around 10:30 AM IST, based on the...

2 months ago - Business Upturn

Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues

Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Dru...

3 months ago - NDTV

Cipla Ltd (BOM:500087) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Margin Challenges

Cipla Ltd (BOM:500087) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Margin Challenges

3 months ago - GuruFocus

Q3 2026 Cipla Ltd Earnings Call Transcript

Q3 2026 Cipla Ltd Earnings Call Transcript

3 months ago - GuruFocus

Cipla shares fall sharply over 3% as Q3 Net profit drops 57.4% YoY to Rs 674.56 crore, EBITDA down 36.7%

Shares of Cipla fell sharply in Friday’s trade after the company reported weak Q3 results, with pressure coming from a...

3 months ago - Business Upturn